AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12470294
Drug: Intravenous anticholinergic
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anticholinergic
Trial: 12470294
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and intradeltoid anticholinergics
Trial: 2586434
Drug: Chemotherapy (control)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (control) group
Trial: 2586434
Drug: OK-432 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OK-432 therapy
Trial: 2586434
Drug: Regional infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regional infusion of LAK cells
Trial: 31282954
Drug: 224 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 224 mg of edonerpic maleate
Trial: 31282954
Drug: 448 mg
RxNorm normalized name: omega-3/dha/epa/fish oil 910 mg (308 mg-448 mg-154 mg)-1,400 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 448 mg of edonerpic maleate
Trial: 28129772
Drug: Iron polymaltose
RxNorm normalized name: iron polymaltose
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron polymaltose (IPM) 6 mg elemental iron/kg/day for 8 weeks
Trial: 28129772
Drug: Iron polymaltose
RxNorm normalized name: iron polymaltose
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron polymaltose (IPM) in iron-replete children (serum ferritin ≥30 µg/l)
Trial: 28129772
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in iron-replete children (serum ferritin ≥30 µg/l)
Trial: 28913922
Drug: Hydroxyurea therapy
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea therapy
Trial: 14640239
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron dextran (IVFe) infusion to achieve target serum ferritin concentrations of 200 ng/ml
Trial: 14640239
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron dextran (IVFe) infusion to achieve target serum ferritin concentrations of 400 ng/ml
Trial: 10850936
Drug: HMB/Arg/Gln mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB/Arg/Gln mixture (3 g HMB, 14 g L-glutamine, and 14 g L-arginine given in two divided doses daily for 8 weeks)
Trial: 8450520
Drug: Elemental calcium
RxNorm normalized name: Elemental calcium
DrugBank: Calcium (DB01373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental calcium (2 g) for 12 weeks
Trial: 6330871
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg at night)
Trial: 3532297
Drug: Pirenzepine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (50 mg at night)
Trial: 3532297
Drug: Antacids (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids (as needed for symptomatic relief)
Trial: 30368033
Drug: Food-based micronutrient
RxNorm normalized name: food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food-based micronutrient supplement with loyalty cards
Trial: 30368033
Drug: Food-based micronutrient
RxNorm normalized name: food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food-based micronutrient supplement with price discounts
Trial: 30368033
Drug: Retail distribution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retail distribution of micronutrient supplements
Trial: 27393520
Drug: 0.45 mg
RxNorm normalized name: urea 0.45 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 mg oral conjugated equine estrogens (CEE)
Trial: 27393520
Drug: Transdermal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2 (50 μg/d) with micronized P (200 mg daily)
Trial: 25027615
Drug: Dextromethorphan hydrobromide
RxNorm normalized name: Dextromethorphan Hydrobromide
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan hydrobromide (DM) syrup, age-weight dosing schedule (DM range 7.5-24.75 mg for Groups A and B; 30 mg for Group C)
Trial: 25027615
Drug: Dextromethorphan hydrobromide
RxNorm normalized name: Dextromethorphan Hydrobromide
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan hydrobromide (DM) syrup
Trial: 22419715
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist stimulation (buserelin 100 μg, s.c.) during hyperinsulinemic clamp (80 mU/m2 · min)
Trial: 22419715
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist stimulation (buserelin 100 μg, s.c.) during saline infusion
Trial: 22419715
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist stimulation (buserelin 100 μg, s.c.) during both hyperinsulinemia and saline infusion
Trial: 18616643
Drug: Nitazoxanide 500
RxNorm normalized name: nitazoxanide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 500 mg tablet twice daily for 24 weeks
Trial: 18616643
Drug: Nitazoxanide 500
RxNorm normalized name: nitazoxanide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 500 mg tablet
Trial: 16088104
Drug: Dialysate bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate bicarbonate at 32 mmol/l (modality A)
Trial: 16088104
Drug: Dialysate bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate bicarbonate at 26 mmol/l (modality B)
Trial: 16088104
Drug: Dialysate calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate calcium at 1.50 mmol/l (modality C)
Trial: 16088104
Drug: Subgroup analysis
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup analysis of modality A with ACE inhibitors or angiotensin II blockers
Trial: 10613449
Drug: Carboplatin (CBP)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (CBP) 200 mg/m2/day continuous infusion (days 3 to 7) with idarubicin (IDA) 12 mg/m2/day i.v. bolus (days 1 to 3)
Trial: 10613449
Drug: Carboplatin (CBP)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (CBP) 200 mg/m2/day continuous infusion (days 3 to 7) with mitoxantrone (MIT) 12 mg/m2/day i.v. bolus (days 1 to 3)
Trial: 8526957
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg mivacurium (2 x ED95)
Trial: 8526957
Drug: 0.015 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.015 mg/kg mivacurium (20% of ED95) followed by 0.07 mg/kg mivacurium (ED95)
Trial: 8526957
Drug: 0.46 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.46 mg/kg atracurium (2 x ED95)
Trial: 8526957
Drug: 0.046 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.046 mg/kg atracurium (20% of ED95) followed by 0.23 mg/kg atracurium (ED95)
Trial: 1835110
Drug: Nebulised ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised ipratropium 0.5 mg and fenoterol 1.25 mg
Trial: 31152023
Drug: Regimen-DI (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen-DI (doxorubicin 6×75 mg/m2/week; cisplatin 6×100 mg/m2/week every 2 weeks)
Trial: 31152023
Drug: Regimen-C (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen-C (doxorubicin 6×75 mg/m2/week; cisplatin 6×100 mg/m2/week every 3 weeks)
Trial: 28952166
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Haloperidol and Olanzapine)
Trial: 18021533
Drug: Control (non-antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non-antiviral interventions)
Trial: 16330292
Drug: 5 puffs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 puffs of oral insulin spray
Trial: 16330292
Drug: 10 puffs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 puffs of oral insulin spray
Trial: 16330292
Drug: 20 puffs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 puffs of oral insulin spray
Trial: 16330292
Drug: Subcutaneously injected
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously injected regular insulin (0.1 U/kg SC)
Trial: 9558132
Drug: Exogenous melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous melatonin administered 5 hours before DLMO
Trial: 31531896
Drug: Dynamic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic treatment regimes (DTRs) for chronic periodontitis
Trial: 31531896
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment sharing
Trial: 24369765
Drug: Low calorie
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calorie dietary advice + placebo (1 g olive oil)
Trial: 24369765
Drug: Low calorie
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calorie dietary advice emphasising fish diet + LCn3PUFA supplements
Trial: 21366361
Drug: Dalcetrapib 3900
RxNorm normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalcetrapib 3900 mg single dose
Trial: 21366361
Drug: Dalcetrapib 1800-3900
RxNorm normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalcetrapib 1800-3900 mg/day for 7 days
Trial: 11743900
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg sustained-release theophylline preparation twice daily for 4 weeks
Trial: 9210705
Drug: In situ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In situ detection of HCV in liver tissue using a combination of nonradioactive in situ hybridization and immunohistochemistry.
Trial: 7950222
Drug: Geng‐Nian‐Shu (GNS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geng‐Nian‐Shu (GNS) treatment
Trial: 7950222
Drug: Geng‐Nian‐Shu (GNS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geng‐Nian‐Shu (GNS) treatment in ovariectomized white rats
Trial: 31595459
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol sedation
Trial: 28806908
Drug: OPT OUT
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OPT OUT - providing all smokers with tobacco-cessation treatment unless they refuse it
Trial: 28806908
Drug: OPT IN
RxNorm normalized name: Glau-Opt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPT IN - current practice of screening for readiness and only offering treatment to smokers who say they are ready to quit
Trial: 18705917
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 64 mmol/day (16 g/day)
Trial: 12826550
Drug: Ropivacaine 0.1%
RxNorm normalized name: ROPivacaine 0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.1% with 0.5 microg x mL(-1) sufentanil (Group R+S0.5)
Trial: 12826550
Drug: Ropivacaine 0.1%
RxNorm normalized name: ROPivacaine 0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.1% with 0.75 microg x mL(-1) sufentanil (Group R+S0.75)
Trial: 12826550
Drug: Ropivacaine 0.1%
RxNorm normalized name: ROPivacaine 0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.1% with 1 microg x mL(-1) sufentanil (Group R+S1)
Trial: 8782501
Drug: Ethanol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (50 ml of 40 percent ethanol)
Trial: 29655114
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy and antidepressants (sertraline and mianserin)
Trial: 12732833
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid solution G
Trial: 12732833
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid solution R
Trial: 11048353
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) plus disulfiram
Trial: 11048353
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) without disulfiram
Trial: 11048353
Drug: Disulfiram (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (in combination with any treatment)
Trial: 11048353
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of abstinence during treatment
Trial: 8622066
Drug: Amsacrine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amsacrine (100 mg/m2/d on days 1 to 5) and Etoposide (200 mg/m2/d on days 1 to 3)
Trial: 8622066
Drug: Amsacrine and
RxNorm normalized name: amsacrine
DrugBank: Amsacrine (DB00276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amsacrine and Etoposide plus Azacitidine (250 mg/m2/d on days 4 to 50)
Trial: 1473880
Drug: Buffered acetylsalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered acetylsalicylic acid (800 mg)
Trial: 1473880
Drug: Unbuffered acetylsalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unbuffered acetylsalicylic acid (500 mg)
Trial: 22326828
Drug: Intratarsal triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratarsal triamcinolone acetonide (TA) injection
Trial: 22340928
Drug: Dexamethasone ointment
RxNorm normalized name: DEXAMETHASONE 0.075 g in 100 g TOPICAL OINTMENT [Seacall Dexamethasone Ointment.]
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone ointment
Trial: 17587715
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum IL-10 level (>= 30 pg/ml)
Trial: 17587715
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum IL-10 level (<30 pg/ml)
Trial: 10767816
Drug: ACTIVE treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTIVE treatment (24 sessions of proprioceptive exercises, relaxation, and behavioral support)
Trial: 10767816
Drug: HOME treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOME treatment (neck lecture and two sessions of practical training for home exercises)
Trial: 10767816
Drug: CONTROL treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CONTROL treatment (lecture regarding care of the neck with a recommendation to exercise)
Trial: 31497883
Drug: Systemic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic Therapy Inventory of Change (STIC) feedback system (ROM condition)
Trial: 31497883
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU condition)
Trial: 23155977
Drug: Ketamine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine group (intravenous ketamine 0.15 mg/kg pre-induction)
Trial: 18069036
Drug: Monthly oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly oral ibandronate 150mg for 3 months
Trial: 18069036
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral alendronate 70mg for 12 weeks
Trial: 16411527
Drug: standard glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard glucose solutions (1.36%)
Trial: 2059395
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 to 8 mg/day)
Trial: 2059395
Drug: Spironolactone (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (37.5 to 75 mg/day)
Trial: 24712568
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg T enanthate
Trial: 24712568
Drug: 6.25 mg
RxNorm normalized name: captopril 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.25 mg T enanthate
Trial: 24712568
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg T enanthate
Trial: 11788637
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg T enanthate
Trial: 21306209
Drug: Ramelteon up
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramelteon up to 16 mg nightly
Trial: 18543495
Drug: Safflor yellow
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflor yellow powder injection (150 mg/d) + Benazepril (10 mg/day)
Trial: 18543495
Drug: Benazepril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (10 mg/day)
Trial: 10080880
Drug: EPO+high Fe
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPO+high Fe (200 U/kg/other day of rhEPO + 12 mg/kg/day of iron)
Trial: 10080880
Drug: EPO+standard Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPO+standard Fe (200 U/kg/other day of rhEPO + 4 mg/kg/day of iron)
Trial: 10080880
Drug: Standard Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Fe (4 mg/kg/day of iron only)
Trial: 2202451
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg prednisolone daily
Trial: 2202451
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg prednisolone daily
Trial: 31654779
Drug: Teriparatide (20μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20μg subcutaneous daily)
Trial: 31654779
Drug: Benzodiazepines/hypnotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepines/hypnotics
Trial: 31654779
Drug: Risedronate (35mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (35mg oral weekly)
Trial: 31010058
Drug: High fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fat oral nutritional supplement (HFS)
Trial: 19300423
Drug: 4.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 g/day CLA with 37.5 mg/day ramipril
Trial: 19300423
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 37.5 mg/day ramipril
Trial: 15352910
Drug: Orlistat treatment
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat treatment for 6 months
Trial: 11672759
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg intravenous acetylsalicylic acid (ASA)
Trial: 26183588
Drug: Physical therapists'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapists' treatment orientations or attitudes
Trial: 25424931
Drug: Vaccine recipients
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine recipients (large-scale cohort)
Trial: 23512639
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) + venlafaxine extended-release (VXR)
Trial: 23512639
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) or LDX + venlafaxine extended-release (VXR)
Trial: 20518254
Drug: MAK (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAK (1.5 g/day) for 12 months
Trial: 12412571
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for Helicobacter pylori eradication
Trial: 1827125
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day CPA
Trial: 6261782
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg oral salbutamol
Trial: 27822319
Drug: DHA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish oil (800 mg DHA/day)
Trial: 19049481
Drug: Spironolactone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (100 mg three times daily)
Trial: 12936920
Drug: Test meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test meal + 0.5 g alcohol/kg body wt (M+A)
Trial: 10762288
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose GH therapy (1 U (0.5 mg) subcutaneously per day, n = 5)